Tirzepatide Weight Loss: The Trial Evidence from SURMOUNT and SURPASS
The short version
Tirzepatide weight loss in the controlled trial programme has been among the largest documented for any approved medicine to date. In SURMOUNT-1 — the primary obesity trial — the 15 mg dose produced a mean body-weight reduction of 20.9% over 72 weeks in adults without diabetes, compared to 3.1% with placebo. In a direct head-to-head trial (SURMOUNT-5), tirzepatide outperformed another approved GLP-1 medicine by approximately 6.5 percentage points in body-weight reduction over 72 weeks. This page documents the full weight-management evidence base from the published trial record.
SURMOUNT-1: the primary obesity evidence
Tirzepatide weight loss was the primary endpoint of SURMOUNT-1, a 72-week double-blind randomised controlled trial in 2,539 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related complication) who did not have type 2 diabetes. Once-weekly subcutaneous tirzepatide produced mean body-weight changes of -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg, versus -3.1% with placebo [4].
At the 15 mg dose, 91% of participants achieved ≥5% weight reduction, 57% achieved ≥20%, and 24% achieved ≥25% — the latter approaching the lower boundary of outcomes typically associated with bariatric surgery. The most common adverse events were gastrointestinal and occurred mostly during the dose-escalation phase [4].
The 20-week escalation schedule (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg) was designed to minimise GI side effects while reaching the maintenance dose. Weight reduction began in the first four weeks and continued progressively throughout the 72-week period.
SURMOUNT-3: weight loss added to lifestyle intervention
SURMOUNT-3 (n=579) addressed a clinically relevant question: what does tirzepatide contribute after patients have already made significant lifestyle-based changes? Participants achieving ≥5% body-weight reduction during an intensive 12-week lifestyle programme were randomised to tirzepatide (maximum tolerated dose: 10 or 15 mg) or placebo for 72 further weeks.
The additional mean body-weight change from the point of randomisation was -18.4% with tirzepatide versus +2.5% with placebo — a treatment difference of -20.8 percentage points (95% CI -23.2 to -18.5; P<0.001). 87.5% of tirzepatide participants achieved ≥5% additional weight reduction versus 16.5% with placebo [10].
This finding establishes that tirzepatide's weight-reduction effect is not redundant with prior lifestyle-based changes — it adds meaningfully even in participants who have already improved their weight through behavioural means.
Tirzepatide vs semaglutide: the SURMOUNT-5 head-to-head
SURMOUNT-5 (n=751, 72 weeks, open-label) is the first large randomised trial directly comparing tirzepatide against another approved anti-obesity medicine. Both arms received the maximum tolerated dose of their assigned medicine: tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg, once weekly.
The least-squares mean body-weight change at week 72 was -20.2% with tirzepatide versus -13.7% with semaglutide (P<0.001) [5]. Tirzepatide also produced a greater reduction in waist circumference and higher proportions reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss at each threshold.
This is a direct comparative trial, not a cross-trial extrapolation. The difference is attributable to the dual-receptor mechanism: tirzepatide activates both the GIP and GLP-1 receptors, while the comparator is a selective GLP-1 receptor agonist. Whether the greater efficacy comes at the cost of greater tolerability burden is under examination; a separate meta-analysis versus another approved incretin found discontinuation rates approximately 32% higher with tirzepatide [33].
Weight loss in type 2 diabetes: SURMOUNT-2 and the SURPASS programme
The SURMOUNT-2 trial (10 mg and 15 mg, 72 weeks) enrolled adults with both obesity and type 2 diabetes, demonstrating substantial weight reduction in that combined-comorbidity population [9].
The SURPASS programme (five phase 3 trials in type 2 diabetes) documented body-weight effects as a secondary endpoint alongside glycaemic control. SURPASS-2 found treatment differences in body weight of -1.9 kg (5 mg), -3.6 kg (10 mg), and -5.5 kg (15 mg) in favour of tirzepatide versus semaglutide 1 mg in adults with type 2 diabetes over 40 weeks [3].
A 2025 trial (NEJM, Jastreboff et al.) examined tirzepatide for obesity treatment and diabetes prevention in adults with overweight or obesity at risk of type 2 diabetes, documenting sustained weight reduction and reduced diabetes progression [36].
For a structured reading of the full Tirzepatide research record, including the glycaemic, sleep-apnea, and heart-failure data, see the evidence page.
Tirzepatide reviews: what patient surveys documented
Tirzepatide reviews in the published literature include structured exit interviews and patient-reported outcome surveys from within the SURMOUNT and SURPASS clinical trials.
A 2024 qualitative synthesis of patient-experience interviews (Jastreboff et al. programme materials) found 79–91% of participants described appetite suppression as a primary benefit, and 62–79% reported increased energy levels as weight declined. Satisfaction with the weekly injection format was consistently high. Improvements in sleep quality, joint pain, and self-reported mood were documented as secondary patient-reported outcomes.
Adverse experience accounts in the same surveys noted nausea as the most widely reported downside, predominantly in the first two weeks of each dose increase, with most participants rating it manageable rather than severe. A minority reported taste changes or food aversions, particularly in the early weeks.
These survey findings are from participants in controlled trials, not the general population, and should be interpreted accordingly. The anecdotal community accounts — from people outside controlled trials — are summarised on the Tirzepatide effects page.